ASCO 2017- A phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in RRMM
Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody, which kills tumor cells via multiple mechanisms. Here, we report preliminary data from the dose-escalation cohorts, and the first 3 pa...
Author: InternationalMyelomaFoundation
Added: 08/15/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2017 Category: Cancer & Oncology Source Type: podcasts
Effects on dexamethasone on sore throat symptoms, prenatal SSRI exposure and autism, comparison of lipid guidelines, and more
Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the April 18, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - April 18, 2017 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Dexamethasone Without Antibiotics vs Placebo on Acute Sore Throat
Interview with Gail Hayward, MA (Oxon) D.Phil MRCP MRCGP, author of Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults: A Randomized Clinical Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - April 18, 2017 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
How do Revlimid and dexamethasone work together against myeloma?
In this weeks video, Dr. Brian Durie addresses a patients concern about continued use of dexamethasone with Rev/dex combination therapy.<br /><br />BOTTOM LINE: <br /><br />Rev/dex is great for initial therapy, but...
Author: MultipleMyeloma
Added: 11/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 22, 2016 Category: Cancer & Oncology Source Type: podcasts
Can Reducing a Dose of Myeloma Maintenance Therapy Increase Risk of Relapse?
In this Ask the Expert segment, Terry is concerned about his mother’s treatment and side effects. He wants to know if a reduction of the dose of Revlimid and dexamethasone will make the treatment less...
Author: P2Professional
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
Can Reducing a Dose of Myeloma Maintenance Therapy Increase Risk of Relapse?
In this Ask the Expert segment, Terry is concerned about his mother’s treatment and side effects. He wants to know if a reduction of the dose of Revlimid and dexamethasone will make the treatment less...
Author: patientpower
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: When will the daratumumab triplet combination be approved for multiple myeloma?
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. Daratu...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: Why daratumumab is effective in multiple myeloma - results from the CASTOR trial
Antonio Palumbo, MD from the University of Turin, Turin, Italy gives an overview of the results of the Phase III CASTOR trial of daratumumab with bortezomib and dexamethasone (NCT02136134). This combi...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: The benefits of lenalidomide and dexamethasone
Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear benefits to receiving lenalidomide and dexamethasone b...
Author: VJHemOnc
Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase III POLLUX trial on (NCT02076009) on combining daratumumab with lenalidomide and dexamethasone vs len...
Author: VJHemOnc
Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Abstract: Ibrutinib with Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use of ibrutinib in combination with low-dose dexamethasone in patients with relapsed ...
Author: imedex
Added: 05/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone i...
Author: VJHemOnc
Added: 02/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 11, 2016 Category: Cancer & Oncology Source Type: podcasts
Transplant vs bortezomib and LEN/DEX in multiple myeloma
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for ...
Author: VJHemOnc
Added: 02/10/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 10, 2016 Category: Cancer & Oncology Source Type: podcasts
Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with r...
Author: VJHemOnc
Added: 02/09/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2016 Category: Cancer & Oncology Source Type: podcasts
